Sirona Biochem Corp. (SBM.V)
| Previous Close | 0.0500 |
| Open | 0.0400 |
| Bid | 0.0400 x 0 |
| Ask | 0.0500 x 0 |
| Day's Range | 0.0400 - 0.0400 |
| 52 Week Range | 0.0400 - 0.1200 |
| Volume | |
| Avg. Volume | 43,609 |
| Market Cap | 10.273M |
| Beta (5Y Monthly) | -0.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0000 |
| Earnings Date | Sept 27, 2024 - Oct 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Dec 27, 2006 |
| 1y Target Est | N/A |
GlobeNewswireGlycoProteMim Featured in Stonegate Healthcare’s Latest Anti-Aging Research Report
VANCOUVER, British Columbia, June 18, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is pleased to announce that its innovative anti-aging ingredient, GlycoProteMim™, has been featured in Stonegate Healthcare's newly published research report, "Novel Treatments for Age-Related Skin Problems." The report provides an in-depth analysis of the latest advancements in the $12.5 billion anti-aging skincare market. The research highlights GlycoProteMim alongside other
NewsfileStonegate Healthcare Partners Announces Publication of Thematic Report on Anti-Aging Dermatology Innovations
Dallas, Texas--(Newsfile Corp. - June 18, 2024) - Stonegate Healthcare Partners, a leading name in healthcare consultancy and market intelligence, is pleased to announce the publication of a comprehensive thematic report titled "Leading Innovations in Anti-Aging Dermatology." This report delves into the transformative advancements in the treatment of age-related skin conditions, focusing on cutting-edge technologies and personalized holistic ...
- GlobeNewswire
Sirona Biochem Engages Stonegate Healthcare Partners
VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) has announced a partnership with Stonegate Healthcare Partners. Stonegate is a leading corporate advisory firm based in Dallas, Texas that offers research driven business development and investor outreach services. Leveraging Stonegate’s extensive global network of corporate and institutional investor relationships, Stonegate has begun an evaluation of Sirona’s anti-aging ingre
